FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileNeuroSense Therapeutics Ltd.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
NRSNW
NeuroSense Therapeutics Ltd. Stock AnalysisComprehensive stock analysis for NeuroSense Therapeutics Ltd. (NRSNW) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisNRSNW
NRSNW
NeuroSense Therapeutics Ltd.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
NRSNW
  1. Home
  2. Stocks
  3. NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Ltd.

🇺🇸NRSNW•NASDAQ

NeuroSense Therapeutics Ltd.

🇺🇸NRSNW•NASDAQ
Market cap
$120.87K

Your view on NRSNW

Mkt Cap
$120.87K
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About NeuroSense Therapeutics Ltd.

Industry
Biotechnology
Sector
Healthcare
CEO
Alon Ben-Noon
Headquarters
Medinat ha-Yehudim Street 85, Herzliya, TA, IL
Industry
Biotechnology
Sector
Healthcare
CEO
Alon Ben-Noon
Headquarters
Medinat ha-Yehudim Street 85, Herzliya, TA, IL
Description

NeuroSense Therapeutics Ltd. is an Israeli clinical-stage biotechnology firm dedicated to pioneering novel therapies for severe neurodegenerative conditions. Its most advanced investigational asset is PrimeC, an innovative oral compound specifically engineered to address amyotrophic lateral sclerosis (ALS).

Beyond its lead program, the company boasts a preclinical pipeline featuring StabiliC, aimed at Parkinson's disease, and CogniC, targeting Alzheimer's disease. Established in Herzliya, Israel, in 2017, NeuroSense Therapeutics continues to advance its therapeutic initiatives.

Financial Data

Stock Data

Price chart, volume, and trading data.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for NeuroSense Therapeutics Ltd.. Starting points for NeuroSense Therapeutics Ltd.: EPS -$6.86, beta 1.60 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for NeuroSense Therapeutics Ltd.. Trailing twelve-month EPS for NeuroSense Therapeutics Ltd. stands at -$6.86. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for NeuroSense Therapeutics Ltd.. NeuroSense Therapeutics Ltd. has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold NRSNW12 companies
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
BETR.CNBetterLife Pharma Inc.HealthcareCNQ—
BETRFBetterLife Pharma Inc.HealthcareOTC$6.4M
BHVNBiohaven Ltd.HealthcareNYSE$1.9B
BICTFBiocure Technology Inc.HealthcareOTC$379,088
BIOABioAge Labs, Inc.HealthcareNASDAQ$161.1M
BIOAFBioasis Technologies Inc.HealthcareOTC$15,883
BIORQBiora Therapeutics, Inc.HealthcarePNK—
BIT.AXBiotron LimitedHealthcareASX—
BITRFBiotron LimitedHealthcareOTC$29.2M
BIVIBioVie Inc.HealthcareNASDAQ$8.6M
BIXTBioxytran, Inc.HealthcareOTC$3.6M
BLAB.CNBritannia Life Sciences Inc.HealthcareCNQ$13.0M
Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold NeuroSense Therapeutics Ltd., and how their positions are changing. At a $120,867 market value, institutional positions materially move NeuroSense Therapeutics Ltd.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by NeuroSense Therapeutics Ltd. executives and directors. Shares of NeuroSense Therapeutics Ltd. have traded between $0.06 and $0.30 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for NeuroSense Therapeutics Ltd.. Coverage tracks NeuroSense Therapeutics Ltd. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of NeuroSense Therapeutics Ltd.

NRSNW AnalysisFair
Past
1
Growth
2
Health
5
Profit
1
Value
1